Content Conference Coverage Conferences ASM Microbe 2016
ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney Safety
- Details
- Category: HIV Treatment
- Created on Sunday, 10 July 2016 00:00
People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements in bone density and kidney function biomarkers, according studies presented at the 2016 ASM Microbe conference last month in Boston.
ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies
- Details
- Category: HIV Treatment
- Created on Monday, 04 July 2016 00:00
Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favorable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity in laboratory and human studies, according to a set of posters presented at ASM Microbe 2016 last month in Boston.
ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression
- Details
- Category: HIV Treatment
- Created on Wednesday, 29 June 2016 00:00
People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.
Coverage of ASM Microbe 2016 (ICAAC 2016)
- Details
- Category: HIV Treatment
- Created on Friday, 01 July 2016 00:00
HIVandHepatitis.com coverage of ASM Microbe 2016 -- a new conference incorporating the American Society for Microbiology annual meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) -- Boston, June 16-20, 2016.
Highlights of this year's conference include antiretroviral drugs and treatment strategies, HIV pre-exposure prophylaxis (PrEP), microbiome research, antibiotic resistance, and emerging viruses including Zika.
Full coverage listing by topic
7/1/16
ASM Microbe 2016: PRO 140 Antibody Injections Maintain Viral Suppression Off ART
- Details
- Category: Experimental HIV Drugs
- Created on Wednesday, 22 June 2016 00:00
Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.
Web Design and Development by